China Digest: Muliang eyes $40m Nasdaq IPO; neoX Biotech, Resproly raise fresh capital
Source: Markus Winkler/Unsplash
February 2, 2021
Chinese fertiliser producer Muliang is seeking to raise $40 million in a Nasdaq IPO, while biotech startup neoX Biotech and inhalation therapy developer Resproly have closed new funding rounds to expand operations.
Fertiliser producer Muliang to raise $40m in Nasdaq IPO
Chinese fertiliser producer Muliang Viagoo Technology (MLVG) is seeking to raise $40 million on the Nasdaq this week by offering 10 million shares at a price of $4 apiece. At the proposed deal size, Muliang would command a market cap of $194 million.
Formed in 2014 under the laws of the state of Nevada, US, Muliang conducts business primarily through Shanghai Muliang, a variable interest entity (VIE) created under the laws of China, to engage in the manufacturing and distribution of organic fertilisers and the sales of agricultural products in China. Its organic fertiliser produ
Chinese printing technology firm Apexmic bags $488m strategic investment led by ICF Premium
Apex Microelectronics Co., Ltd (Apexmic), a wholly-owned subsidiary of Shenzhen-listed Ninestar Corporation that offers printing and imaging services, has received a 3.2 billion yuan ($488 million) strategic investment led by state-owned China Integrated Circuit Industry Investment Fund (ICF) II, according to a company filing with The Stock Exchange of Shenzhen on December 8.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday